ASCO CAR-T Highlights: Exploring New Frontiers For The Field
As Novartis awaits word from FDA on its CTL019, company trumpets potential of its "next-generation" CAR-T therapy CTL119 in combination with Imbruvica, with data from a small pilot study being presented at ASCO.
You may also be interested in...
CEO Joe Jimenez told investors the firm is encouraged about the commercial prospects for CAR-T therapy. Lead drug CTL019 made Novartis' list of blockbusters in development after having been left off last year.
Keeping Track: US FDA Approvals Binge Continues With Dupixent, Ocrevus And Zejula; Two CAR-T Are Under Review
The latest drug development news and highlights from our US FDA Performance Tracker.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.